DJIA 17,688.26 -57.72 -0.33%
NASDAQ 5,129.37 0.58 0.01%
S&P 500 2,103.77 -4.86 -0.23%
market minute promo

Targacept , Inc. (NASDAQ: TRGT)

2.47 -0.01 (-0.40%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TRGT $2.47 -0.40%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.44
Previous Close $2.48
Daily Range $2.40 - $2.50
52-Week Range $2.15 - $3.23
Market Cap $83.7M
P/E Ratio -3.40
Dividend (Yield) $0.00 (0.0%)
Volume 9,670
Average Daily Volume 53,170
Current FY EPS -$0.89

Sector

Healthcare

Industry

Drug Makers

Targacept , Inc. (TRGT) Description

A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Website: http://www.targacept.com/

News & Commentary

Keep an Eye on Biogen, Johnson & Johnson, and Merck Today

Biogen, Johnson & Johnson, and Merck could all make health care headlines this morning. Here’s all the news you need to know.

Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation

Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation Coagulation Factor VIIa in Patients With Hemophilia A or B and Preclinical Results

Targacept and Catalyst Biosciences Amend Definitive Merger Agreement

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog

Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastropa

Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Pres

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blo

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog

Targacept Crumbles as Pfizer Pulls Out of Collaboration - Analyst Blog

Why I Am Still Long Targacept After The Reverse Merger Announcement

Targacept Management Increases Urgency And Aims For Q4 Strategic Action

See More TRGT News...

TRGT's Top Competitors

TRGT $2.47 (-0.40%)
Current stock: TRGT
AMGN $176.66 (2.89%)
Current stock: AMGN
GILD $117.71 (-0.16%)
Current stock: GILD
BIIB $318.74 (0.55%)
Current stock: BIIB